drugset / Trial / NCT06367153
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
NaCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide, midazolam and bupropion (i.e. sensitive CYP2C8, CYP3A4 and CYP2B6 substrates).
Timeline
- Start
- 2024-05-15
- Primary completion
- 2024-08-20
- Completion
- 2024-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1569912 | Unknown | — | Oral |
| Subject | Bupropion | Small molecule | 150 mg | — |
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Repaglinide | Small molecule | 0.5 mg | Oral |
Indications
No indication recorded.